Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Continuous Glucose Monitoring Improves Glycemic Control in Diabetes
Última actualización 15 de junio de 2026
Key finding
HbA1c decreased from 8.09% to 7.48% (p < 0.001).
This study examined the impact of continuous glucose monitoring on glycemic control in diabetes patients, finding significant reductions in HbA1c and fasting plasma glucose levels.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study examined the impact of continuous glucose monitoring on glycemic control in diabetes patients, finding significant reductions in HbA1c and fasting plasma glucose levels.
Clinical relevance
Improving glycemic control is crucial for diabetes management, as it can reduce the risk of complications associated with the disease. The significant reductions in HbA1c and fasting plasma glucose suggest that continuous glucose monitoring could be an effective tool for patients and healthcare providers aiming to enhance diabetes care.
Keep in mind
Study design was non-randomized, limiting causal inference. Sample size and demographic details were not specified. Potential confounding factors were not controlled.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Mi-Joon L, Bum-Jeun S, Jae-Hyoung C, Daniela MT, Mariana F, Ionela LS. The Effects of Continuous Glucose Monitoring on Glycemic Control in Patients with Diabetes Mellitus. Life. 2025;15(10):1543. doi:10.3390/life15101543
Efectos Principales
HbA1c decreased from 8.09% to 7.48% (p < 0.001)
Fasting plasma glucose decreased from 152.41 mg/dL to 137.16 mg/dL (p < 0.001)
Total cholesterol decreased from 149.77 mg/dL to 146.95 mg/dL (p = 0.036)
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Continuous glucose monitoring and BMI, Fasting blood sugar (FBS), HbA1c, and 1 more.
This study contributes evidence to
Primary intervention
Continuous glucose monitoring
Primary outcomes
- BMI
- Fasting blood sugar (FBS)
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
4
Related topics
4
Evidence pairs
888
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Insulin Delivery Systems and HbA1c
Evidencia relacionada
Relación de evidencia
Insulin Delivery Systems and Fasting Glucose
Guardar evidencia
Relación de evidencia
Insulin Delivery Systems and Adipokine and Angiogenic Markers
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Fasting blood sugar (FBS)
Continuous glucose monitoring → Fasting blood sugar (FBS)
Continuous glucose monitoring → Fasting blood sugar (FBS)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 93
- Very Positive
- ConsistencyScore™
- 86
- consistent
Estudios de apoyo: Basado en 7 estudios
Add to Evidence TrackerTotal cholesterol
Continuous glucose monitoring → Total cholesterol
Continuous glucose monitoring → Total cholesterol
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- HbA1c decreased by 0.61% (p < 0.001).
- Fasting plasma glucose decreased by 15.25 mg/dL (p < 0.001).
- Total cholesterol decreased by 2.82 mg/dL (p = 0.036).
A quién se aplica
- Adults diagnosed with diabetes mellitus.
- Patients using continuous glucose monitoring devices.
Tener en Cuenta
- Results may not be generalizable to all diabetes populations.
- The increase in body mass index was not statistically significant.
- Further research is needed to confirm long-term effects.
Entre Líneas
- Study design was non-randomized, limiting causal inference.
- Sample size and demographic details were not specified.
- Potential confounding factors were not controlled.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Delivery Systems and HbA1c, Insulin Delivery Systems and Body Mass Index.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Devices & Technology
Insulin Delivery Systems → HbA1c
Devices & Technology
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 93
- Very Positive
- ConsistencyScore™
- 86
- consistent
Estudios de apoyo: Basado en 7 estudios
View evidenceDevices & Technology
Insulin Delivery Systems → Body Mass Index
Devices & Technology
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceDevices & Technology
Insulin Delivery Systems → Adipokine and Angiogenic Markers
Devices & Technology
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
7 studies
outcome_hubMeasures HbA1c as a key outcome.
Insulin Delivery Systems Evidence Hub
All studies on Insulin Delivery Systems
7 studies
intervention_hubContributes to Insulin Delivery Systems evidence base.
Adipokine and Angiogenic Markers Evidence Hub
All studies measuring Adipokine and Angiogenic Markers
1 studies
outcome_hubMeasures Adipokine and Angiogenic Markers as a key outcome.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
1 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Continuous glucose monitoring and HbA1c
Intervention: Continuous glucose monitoringOutcome: HbA1c
7 results
All studies on Continuous glucose monitoring and BMI
Intervention: Continuous glucose monitoringOutcome: BMI
1 results
All studies on Continuous glucose monitoring
Intervention: Continuous glucose monitoring
7 results
All studies measuring HbA1c
Outcome: HbA1c
7 results
All studies measuring BMI
Outcome: BMI
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Insulin Delivery Systems improve HbA1c?
Strong Evidence
Insulin Delivery Systems appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.3 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Insulin Delivery Systems improve fasting glucose?
Moderate Evidence
Insulin Delivery Systems appears to improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Insulin Delivery Systems affect body mass index?
Emerging Evidence
Current evidence does not show a clear benefit of Insulin Delivery Systems for Body Mass Index.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Insulin Delivery Systems improve adipokine and angiogenic markers?
Emerging Evidence
Insulin Delivery Systems appears to improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Total cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
i3 CGM shows reliable performance for diabetes managementNatural products may improve glycemic control in type 2 diabetesDexcom ONE use significantly reduces HbA1c in diabetes patients.Dietary interventions improve glycemic control in pre-diabetic patientsEducation Model Improves Glycemic Control in Type 1 Diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.